Contrasting Assure (NASDAQ:IONM) and Profound Medical (NASDAQ:PROF)

Profound Medical (NASDAQ:PROF) and Assure (NASDAQ:IONM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability and analyst recommendations.

Volatility and Risk

Profound Medical has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, Assure has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500.

Insider and Institutional Ownership

47.9% of Profound Medical shares are held by institutional investors. Comparatively, 3.3% of Assure shares are held by institutional investors. 1.5% of Profound Medical shares are held by insiders. Comparatively, 3.8% of Assure shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Profound Medical and Assure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Profound Medical	-349.41%	-85.22%	-64.87%
Assure	-25,178.32%	N/A	-249.78%

Valuation & Earnings

This table compares Profound Medical and Assure”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$8.98 million	23.33	-$28.57 million	($1.34)	-5.21
Assure	$149,000.00	0.94	-$26.08 million	N/A	N/A

Assure has lower revenue, but higher earnings than Profound Medical.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Profound Medical and Assure, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	0	0	3	1	3.25
Assure	0	0	0	0	0.00

Profound Medical presently has a consensus target price of $13.75, indicating a potential upside of 96.99%. Given Profound Medical’s stronger consensus rating and higher probable upside, equities analysts plainly believe Profound Medical is more favorable than Assure.

Summary

Profound Medical beats Assure on 9 of the 13 factors compared between the two stocks.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

About Assure

Assure Holdings Corp., through its subsidiaries, provides technical and professional intraoperative neuromonitoring surgical support services in the United States. It offers services in the areas of neurosurgery, spine, cardiovascular, orthopedic, ear, nose, throat, and other surgical procedures. The company delivers various clinical and operational services, including scheduling of the interoperative neurophysiologist and supervising practitioner, real time monitoring, patient advocacy, and billing services to support surgeons and medical facilities during invasive procedures. Assure Holdings Corp. is based in Englewood, Colorado.